Doheny Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Doheny Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$255K	Hold	4,200	–	–	0.17%	52
2025 Q4	$227K	Buy	+4,200	New	+$202K	0.14%	55
2023 Q4	–	Sell	-3,829	Closed	-$222K	–	70
2023 Q3	$222K	Hold	3,829	–	–	0.22%	60
2023 Q2	$245K	Sell	3,829 -100	-3%	-$6.71K	0.21%	63
2023 Q1	$272K	Buy	3,929 +870	+28%	+$61.4K	0.24%	61
2022 Q4	$220K	Sell	3,059 -870	-22%	-$65.6K	0.26%	64
2022 Q3	$279K	Buy	+3,929	New	+$285K	0.28%	62
2022 Q1	$287K	Hold	3,929	–	–	0.21%	67
2021 Q4	$245K	Hold	3,929	–	–	0.17%	80
2021 Q3	$232K	Sell	3,929 -630	-14%	-$41.5K	0.17%	85
2021 Q2	$305K	Hold	4,559	–	–	0.2%	82
2021 Q1	$288K	Hold	4,559	–	–	0.2%	88
2020 Q4	$283K	Sell	4,559 -4,404	-49%	-$271K	0.2%	87
2020 Q3	$540K	Hold	8,963	–	–	0.45%	53
2020 Q2	$527K	Sell	8,963 -490	-5%	-$29.3K	0.5%	50
2020 Q1	$607K	Hold	9,453	–	–	0.48%	58
2019 Q4	$607K	Buy	9,453 +1,505	+19%	+$86.2K	0.48%	58
2019 Q3	$403K	Sell	7,948 -500	-6%	-$23.5K	0.35%	68
2019 Q2	$383K	Buy	8,448 +820	+11%	+$38.2K	0.32%	71
2019 Q1	$364K	Sell	7,628 -250	-3%	-$12.5K	0.31%	75
2018 Q4	$409K	Sell	7,878 -4,200	-35%	-$226K	0.3%	65
2018 Q3	$750K	Hold	12,078	–	–	0.39%	61
2018 Q2	$668K	Sell	12,078 -13,350	-53%	-$721K	0.36%	60
2018 Q1	$1.61M	Sell	25,428 -2,375	-9%	-$153K	0.84%	39
2017 Q4	$1.7M	Sell	27,803 -1,800	-6%	-$113K	0.79%	39
2017 Q3	$1.89M	Buy	29,603 +7,300	+33%	+$426K	0.87%	34
2017 Q2	$1.24M	Sell	22,303 -2,495	-10%	-$136K	0.58%	45
2017 Q1	$1.35M	Sell	24,798 -350	-1%	-$19.2K	0.61%	41
2016 Q4	$1.47M	Sell	25,148 -24,947	-50%	-$1.36M	0.71%	43
2016 Q3	$2.7M	Sell	50,095 -600	-1%	-$38.5K	1.39%	20
2016 Q2	$3.73M	Sell	50,695 -700	-1%	-$49.5K	1.87%	19
2016 Q1	$3.28M	Hold	51,395	–	–	1.69%	21
2015 Q4	$3.54M	Buy	51,395 +1,030	+2%	+$68.1K	1.73%	21
2015 Q3	$2.98M	Buy	50,365 +4,875	+11%	+$309K	1.55%	25
2015 Q2	$3.03M	Buy	45,490 +500	+1%	+$33K	1.35%	24
2015 Q1	$2.9M	Hold	44,990	–	–	1.35%	25
2014 Q4	$2.66M	Buy	44,990 +14,100	+46%	+$795K	1.27%	27
2014 Q3	$1.58M	Sell	30,890 -1,250	-4%	-$62.4K	0.79%	39
2014 Q2	$1.56M	Sell	32,140 -1,800	-5%	-$88.7K	0.74%	43
2014 Q1	$1.76M	Buy	33,940 +250	+0.7%	+$13.3K	0.91%	42
2013 Q4	$1.79M	Buy	33,690 +1,030	+3%	+$52.5K	0.94%	41
2013 Q3	$1.51M	Buy	32,660 +150	+0.5%	+$6.58K	0.83%	45
2013 Q2	$1.45M	Buy	+32,510	New	+$1.41M	0.83%	48

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Doheny Asset Management's BMY Position: Q1 2026 in Review

Doheny Asset Management held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 4,200 shares worth $255K. The position accounts for 0.17% of the portfolio, ranked #52.

Doheny Asset Management first reported a position in BMY in Q2 2013 and has held it in 43 quarters since. The position peaked at $3.73M in Q2 2016. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Doheny Asset Management held 4,200 shares of Bristol-Myers Squibb worth $255K as of Q1 2026.
Doheny Asset Management left its Bristol-Myers Squibb share count unchanged in Q1 2026.
Bristol-Myers Squibb made up 0.17% of Doheny Asset Management's portfolio in Q1 2026, its #52 holding.
Doheny Asset Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 43 quarters since.
Doheny Asset Management's Bristol-Myers Squibb position peaked at $3.73M in Q2 2016.
2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Doheny Asset Management's 13F filing for Q1 2026, filed 7 May 2026.